BridgeBio Pharma (NASDAQ:BBIO) reported quarterly losses of $(1.40) per share which missed the analyst consensus estimate of $(1.14) by 22.81 percent. This is a 45.83 percent decrease over losses of $(0.96) per share from the same period last year. The company reported quarterly sales of $5.88 million which beat the analyst consensus estimate of $3.48 million by 69.05 percent. This is a 237.08 percent increase over sales of $1.75 million the same period last year.